1. Home
  2. GILD vs NVO Comparison

GILD vs NVO Comparison

Compare GILD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

N/A

Current Price

$145.63

Market Cap

184.4B

Sector

Health Care

ML Signal

N/A

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

N/A

Current Price

$38.08

Market Cap

269.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GILD
NVO
Founded
1987
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.4B
269.6B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
GILD
NVO
Price
$145.63
$38.08
Analyst Decision
Strong Buy
Hold
Analyst Count
18
11
Target Price
$146.50
$51.00
AVG Volume (30 Days)
5.7M
18.6M
Earning Date
05-13-2026
01-01-0001
Dividend Yield
2.25%
3.17%
EPS Growth
1684.21
N/A
EPS
6.78
N/A
Revenue
$24,689,000,000.00
N/A
Revenue This Year
$4.68
N/A
Revenue Next Year
$6.10
$3.30
P/E Ratio
$21.53
$13.60
Revenue Growth
9.98
N/A
52 Week Low
$95.30
$35.85
52 Week High
$157.29
$82.23

Technical Indicators

Market Signals
Indicator
GILD
NVO
Relative Strength Index (RSI) 51.02 32.56
Support Level $143.09 $35.85
Resistance Level $157.29 $50.30
Average True Range (ATR) 3.18 0.90
MACD -1.01 0.31
Stochastic Oscillator 37.10 40.55

Price Performance

Historical Comparison
GILD
NVO

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: